Security key
55083R203
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL)
CUSIP: 55083R203
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.0001
- Total 13F shares
- 11,405,527
- Total 13F value
- $350,313,783
- Share change
- +239,937
- SEC-reported price per share
- $30.78
- Number of holders
- 67
- Value change
- +$8,387,255
- Number of buys
- 28
- Number of sells
- 20
- Shares outstanding
- 24,390,244
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
67
Top holders
10
LYEL full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Lyell Immunopharma, Inc. SEC filings
Lyell Immunopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55083R203
Recent filing periods:
Ownership snapshot
Top reported holders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARCH Venture Fund IX, L.P.
Disclosed value leader
ARCH Venture Management, LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 13%
13D/G row: ARCH Venture Fund IX, L.P.
Showing 1-6 of 15 holder rows.
Quick read
ARCH Venture Fund IX, L.P. leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Fund IX, L.P.'s linked filing trail.
Comparable ownership
Top 5
ARCH Venture Fund IX, L.P.
13%
Foresite Capital Fund IV, L.P.
7.6%
Gates Frontier, LLC
5.6%
BlackRock, Inc.
4.5%
NEWTON (PTC) Ltd
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. |
13D/G
|
13%
|
$44,807,053
2,759,072 shares
|
$0 | 30 Sep 2025 |
| Foresite Capital Fund IV, L.P. |
13D/G
James B. Tananbaum
|
7.6%
|
$23,622,818
1,454,616 shares
|
$0 | 30 Sep 2025 |
| Gates Frontier, LLC |
13D/G
|
5.6%
|
$10,628,242
1,040,964 shares
|
$0 | 25 Jul 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
4.5%
|
$6,234,958
13,265,869 shares
|
$0 | 31 Dec 2024 |
| NEWTON (PTC) Ltd |
13D/G
Newton (PTC) Limited
|
3.9%
|
$12,256,220
754,698 shares
|
$0 | 30 Sep 2025 |
| ARCH Venture Management, LLC |
13F
Company
|
11%
|
$44,807,329
2,759,072 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
67
Shares
11,405,527
Rows available
67
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
56
Q4 2025 holders
67
Holder diff
11
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend